| Foot And Surgery Clinic, Inc | |
|
7402 S Siwell Rd, Suite 110, Byram, MS 39272-9386 | |
| (601) 372-3222 | |
| Not Available |
| Full Name | Foot And Surgery Clinic, Inc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot Surgery |
| Location | 7402 S Siwell Rd, Byram, Mississippi |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124479100 | NPI | - | NPPES |
| 00111109 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0131X | Podiatrist - Foot Surgery | 80112 (Mississippi) | Primary |
| Provider Name | Vershern Edwards |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1497905079 PECOS PAC ID: 8123044229 Enrollment ID: I20051018000968 |
News Archive
BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a clinical-stage rare disease and oncology company focused on sourcing and developing innovative treatments for underserved patient populations, announced today that the companies have entered into a global clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene's investigational RAF dimer inhibitor, lifirafenib and SpringWorks Therapeutics' investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors.
Buckeye Health Plan announced today that it's been awarded a Dorland Health Case in Point Award for its Pregnancy Specialty Care Management Program. The Case in Point Platinum Awards recognizes successful case management programs that focus on the continuum of care coordination.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA's proprietary product candidate currently in Phase III development for Parkinson's disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer's disease psychosis (ADP).
The National Alzheimer's Project Act (NAPA) was signed into law in 2011. Over the past five years milestones have been identified to meet the plan's biomedical research goal. However, similar milestones have not been created for the goals on patient care and caregiver support.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Foot And Surgery Clinic, Inc 7402 S Siwell Rd, Suite 110, Byram, MS 39272-9386 Ph: (601) 372-3222 | Foot And Surgery Clinic, Inc 7402 S Siwell Rd, Suite 110, Byram, MS 39272-9386 Ph: (601) 372-3222 |
News Archive
BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a clinical-stage rare disease and oncology company focused on sourcing and developing innovative treatments for underserved patient populations, announced today that the companies have entered into a global clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene's investigational RAF dimer inhibitor, lifirafenib and SpringWorks Therapeutics' investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors.
Buckeye Health Plan announced today that it's been awarded a Dorland Health Case in Point Award for its Pregnancy Specialty Care Management Program. The Case in Point Platinum Awards recognizes successful case management programs that focus on the continuum of care coordination.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA's proprietary product candidate currently in Phase III development for Parkinson's disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer's disease psychosis (ADP).
The National Alzheimer's Project Act (NAPA) was signed into law in 2011. Over the past five years milestones have been identified to meet the plan's biomedical research goal. However, similar milestones have not been created for the goals on patient care and caregiver support.
› Verified 2 days ago